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Significance of this study
What is already known on this subject?
 ► COVID-19 is a global pandemic caused by the 
severe acute respiratory syndrome coronavirus 
2. COVID-19 is highly contagious and causes a 
spectrum of disorders ranging from relatively 
mild symptoms to life- threatening conditions. 
Medical therapies that interrupt COVID-19 
progression in non- hospitalised symptomatic 
patients are therefore highly sought.
What are the new findings?
 ► We devised a method to quantitatively follow 
six common symptoms in non- hospitalised 
patients with COVID-19 over the course of 
their illness. The individually normalised patient 
symptoms revealed that the self- administration 
of the histamine-2 receptor antagonist 
famotidine is associated with symptomatic 
improvements in a case series of 10 consecutive 
patients.
How might it impact on clinical practice in the 
foreseeable future?
 ► Our findings support the rigorous evaluation 
of famotidine as a potential therapy and of the 
use of symptom tracking for non- hospitalised 
patients with COVID-19.
AbSTrACT
Objective Treatment options for non- hospitalised 
patients with coronavirus disease 2019 (cOViD-19) to 
reduce morbidity, mortality and spread of the disease are 
an urgent global need. The over- the- counter histamine-2 
receptor antagonist famotidine is a putative therapy 
for cOViD-19. We quantitively assessed longitudinal 
changes in patient reported outcome measures in 
non- hospitalised patients with cOViD-19 who self- 
administered high- dose famotidine orally.
Design Patients were enrolled consecutively after 
signing written informed consent. Data on demographics, 
cOViD-19 diagnosis, famotidine use, drug- related side 
effects, temperature measurements, oxygen saturations 
and symptom scores were obtained using questionnaires 
and telephone interviews. Based on a national institute 
of health (nih)- endorsed Protocol to research Patient 
experience of cOViD-19, we collected longitudinal 
severity scores of five symptoms (cough, shortness of 
breath, fatigue, headaches and anosmia) and general 
unwellness on a four- point ordinal scale modelled on 
performance status scoring. all data are reported at 
the patient level. longitudinal combined normalised 
symptom scores were statistically compared.
results Ten consecutive patients with cOViD-19 
who self- administered high- dose oral famotidine were 
identified. The most frequently used famotidine regimen 
was 80 mg three times daily (n=6) for a median of 
11 days (range: 5–21 days). Famotidine was well 
tolerated. all patients reported marked improvements of 
disease related symptoms after starting famotidine. The 
combined symptom score improved significantly within 
24 hours of starting famotidine and peripheral oxygen 
saturation (n=2) and device recorded activity (n=1) 
increased.
Conclusions The results of this case series suggest 
that high- dose oral famotidine is well tolerated and 
associated with improved patient- reported outcomes in 
non- hospitalised patients with cOViD-19.
InTrODuCTIOn
Management of patients with coronavirus disease 
2019 (COVID-19), caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS- CoV-2), 
poses a major challenge to the biomedical 
community, governments and global population. 
Currently, most research focuses on vaccine devel-
opment or pharmacological treatment strategies for 
hospitalised patients with COVID-19.1 However, 
to reduce global morbidity and mortality, effective 
treatment strategies for non- hospitalised patients 
are required.
Famotidine may be a candidate medication for 
this. Famotidine is a histamine-2 receptor antago-
nist, widely available over the counter at low cost, 
does not interact with other medications and has 
been safely used for suppression of gastric acid 
production over a wide range of oral doses from 
20 mg once daily to 160 mg four times daily.2 In 
computer simulations, famotidine was identified 
as a potential inhibitor of the 3- chymotrypsin- like 
protease,3 and this and other potential mechanisms 
of action for famotidine in COVID-19 are an area 
of current research. In a propensity score matched 
retrospective cohort study a significantly reduced 
risk for death or intubation (adjusted HR 0.43, 
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Table 1 Patient characteristics
Patient 1 2 3 4 5 6 7 8 9 10
Age range 
(years)
40s 40s 30s 60s 50s 20s 20s 70s 50s 60s
Gender F M M F M F F M M M
Ethnicity White Hispanic Asian Black White Hispanic Black and 
Hispanic
White South Asian White
Height (cm) 163 152 182 163 173 157 175 188 173 191
Weight (kg) 59 100 82 100 79 59 127 96 77 136
BMI 22 43 25 38 27 24 41 27 26 37
Smoking History N Y N Ex Ex N N N Ex Ex
Comorbidities Epilepsy N N HTN HTN and 
hyperlipidaemia
N N Chronic pancreatitis 
and MI
Hyperlipidaemia N
Regular 
medication
Kepra     Nifedipine, 
telmisartan and 
HCT.
Lisinopril and 
atorvastatin.
    Metoprolol, ASA and 
rosuvastatin.
ASA and 
rosuvastatin.
  
Tylenol Once   1–2×/day 1 mg       For 5 days       
Test method Nasal swab 
PCR
Nasal swab
PCR
Nasal swab
PCR
AB test* Nasal swab
PCR
Nasal swab
PCR
Nasal swab
PCR
Clinical diagnosis Nasal swab
PCR
AB test*
Test date 04/03 03/27 03/30 05/01 04/10 04/20 04/20   04/30 04/16 05/04
Start symptoms 03/24 03/25 03/21 04/03 04/10 04/12 04/15 03/10 04/14 03/23
Start Fam. 03/28 04/02 03/30 04/13 04/16 04/21 04/21 04/05 04/16 03/30
Stop Fam. 04/07 04/12 04/05 04/24 04/23 05/08 05/02 04/09 05/06 04/03
Fam. dose 80 mg three 
times a day
80 mg three 
times a day
80 mg three 
times a day
50 mg three times 
a day
80 mg three times 
a day
80 mg three 
times a day
80 mg three 
times a day
60 mg two times 
per day
60 mg two times 
per day
20 mg three 
times a day
Symptoms†                     
  Body ache   Y Y Y     Y   Y   
  Chest 
tightness
      Y Y     Y     
  Others   Sweating. Chills and 
hives.
  Body spasms. Sore throat. Congested 
nose and GI 
symptoms.
Sinusitis/
congested 
nose.
Slow motion 
performance.
GI symptoms and 
dehydration.
Influenza 
symptoms.
AEs           Racing 
heartbeat and 
dizziness.
Dizziness, 
dry skin and 
insomnia.
  (GI symptoms and 
forgetfulness)
  
In order to comply with journal guidelines for anonymisation ages are provided as age ranges.
*Pt 4: test by Mount Sinai Health Systems, USA, titre: 2880; pt 10: test by Mount Sinai Health Systems, USA, titre: 2880.
†In addition to those symptoms scored in the questionnaire; dates displayed as month/day.
AB, antibody; AEs, adverse events, in parenthesis if only possibly related to famotidine; BMI, body mass index; F, female; Fam., famotidine; HCT, hydrochlorothiazide; HTN, hypertension; M, male; N, no; Y, yes.
95% CI 0.21 to 0.88) was identified for patients with COVID-19 
who were incidentally taking famotidine before or at the point 
of hospital admission.4
The incentive for the retrospective cohort study were the 
unexpected positive results from a group of 10 patients who 
took famotidine following onset of symptoms for COVID-19. 
Here, we summarise this series of 10 patients with COVID-19 
who self- medicated with famotidine as outpatients. The patient- 
reported demographics, clinical course, drug tolerability and 
longitudinal symptom scores are provided.
MeTHODS
Consecutive patients were enrolled in this study after signing 
written informed consent for study participation and for deiden-
tified data being reported in a published case series. No participant 
was excluded. Data were collected by two telephone interviews 
and two written questionnaires. Information on patient demo-
graphics, comorbidities, COVID-19 test results, famotidine use, 
drug- related side effects, temperature measurements, oxygen 
saturations and symptom scores were obtained. We collected 
longitudinal severity scores on five symptoms (cough, shortness 
of breath, fatigue, headaches and anosmia), based on an NIH 
endorsed Protocol to research Patient Experience of COVID-
19, in addition to general unwellness.5 Symptom scores were 
retrospectively provided by patients on an ordinal scale: 1=not 
affected, 2=little affected, 3=affected and 4=severely affected. 
This four- point scale was based on performance status scoring in 
patients with cancer who are systemically affected by illness or 
treatment. We adapted the first four scale points of the Eastern 
Cooperative Oncology Group performance status (ECOG PS) 
scale6 and provided explanatory text to the patients as part of 
the symptom questionnaire. We chose only those scale points of 
the ECOG PS as measures of grades of severity that are relevant 
to a severity of COVID-19 illness that does not require hospi-
talisation. The relevant sections of the questionnaire with the 
introduction to the scale and scoring system were provided to 
the participants and are included in the online supplementary 
methods section. Longitudinal symptom scores for the time 
prior to the COVID-19 illness (baseline, B), the day before 
starting famotidine (day −1), the day famotidine was started 
(day 0) and days 1, 2, 7 and 14 after starting famotidine were 
recorded. Longitudinal temperature recordings, pulse oximetry 
and activity monitoring data were recorded when available.
reSulTS
Patient characteristics
Ten individuals with the clinical diagnosis of COVID-19 who 
self- medicated with high dose oral famotidine were identi-
fied. Eight patients were from New York State, one from New 
Jersey and one from Sweden. The characteristics of all study 
participants are summarised in table 1. The study participants 
were diverse with regard to known risk factors for severity of 
COVID-19 illness: age, sex, ethnicity and body mass index 
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Figure 1 Symptomatic days before famotidine start. The durations of 
symptoms prior to starting famotidine are displayed in ascending order 
for individual patients.
(BMI).7 Seven patients had positive PCR- based diagnoses from 
nasal swabs for SARS- CoV-2, two patients had positive sero-
logical tests for antibodies directed against the virus and one 
patient had a clinical diagnosis without molecular confirmation 
(table 1). All started taking famotidine while feeling unwell with 
COVID-19. The most commonly used dose was 80 mg oral 
famotidine three times daily (n=6), and the dose ranged from 
20 mg three times daily to 80 mg three times daily. Median dura-
tion of famotidine self- administration was 11 days (range 5–21 
days). The time period between onset of symptoms and starting 
treatment differed widely between patients, ranging from 2 days 
to 26 days (figure 1).
Patient-reported toxicity
Seven patients did not experience any adverse events. One 
patient reported grade 1 dizziness and very occasional percep-
tions of a racing heartbeat. Another patient experienced grade 1 
dizziness, dry skin and insomnia. A third patient reported grade 
1 gastroenterological symptoms and temporary forgetfulness 
(table 1). Other than forgetfulness, all of these side effects are 
listed in the prescription information for famotidine,2 and all 
side effects resolved on discontinuation of famotidine.
Patient-reported outcomes and symptoms
No hospitalisations were reported by any of the participants, 
and at the point of submission of this manuscript, patients 
reported feeling fully recovered apart from persistent anosmia 
in two cases. All patients were asymptomatic prior to developing 
COVID-19. They all were affected by a wide range of symptoms 
when they were feeling worst, and this was comparable with 
how they felt on the day prior to starting famotidine. On starting 
famotidine, all patients reported improvement of symptoms 
within 24–48 hours (case synopses and figure 2). When we anal-
ysed the changes of the normalised total symptom score across 
all patients, we found no significant difference for the day before 
starting famotidine compared with the day of starting famoti-
dine, but a significant improvement in the symptom score was 
reported within 24 hours of starting famotidine and symptoms 
continued to improve and nearly normalised to preillness levels 
at 14 days after first famotidine use (figure 3). The improvement 
of symptoms was across all categories, but airway- related symp-
toms such as cough and shortness of breath were reported to 
improve more rapidly than systemic symptoms such as fatigue 
(figure 2).
Individual case summaries
Patient 1 is a white woman in her 40s with a medical history of 
epilepsy for which she takes levetiracetam 1 g daily. She took 
famotidine 80 mg three times daily for 11 days starting 4 days 
after first experiencing symptoms of COVID-19. She reported 
feeling very unwell at this time point. Within 1 day of the first dose 
of famotidine, she noticed marked improvement of her shortness 
of breath. This improvement was matched by an increase in her 
home- monitored pulse oximetry measured oxygen saturation 
levels from 91%–95% to 97%–98% (figure 4A). She was febrile 
with a temperature of 37.8°C prior to starting famotidine and 
afebrile on day 7 of taking famotidine.
Patient 2 is a Hispanic man in his 40s without pre- existing 
conditions. He took famotidine 80 mg three times daily for 11 
days starting 8 days after first experiencing symptoms of COVID-
19. He reported improvement of symptoms within 2 days of 
treatment. He was febrile with a temperature of 38.3°C prior to 
starting famotidine and afebrile on day 5 of taking famotidine.
Patient 3 is an Asian man in his 30s without pre- existing 
conditions. He took famotidine 80 mg three times daily for 
7 days starting 9 days after first experiencing symptoms of 
COVID-19. He experienced severe shortness of breath prior 
to starting famotidine, and his dyspnoea and other symptoms 
improved by day 7. His home monitored oxygen saturation 
levels improved from 89% on day 2 of treatment to 96% on 
day 5 of treatment (figure 4A). He was febrile with a tempera-
ture of 38.9°C prior to starting famotidine and afebrile on day 
5 of taking famotidine. He intermittently took paracetamol for 
fever during illness.
Patient 4 is a black woman in her 60s with a BMI of 38, 
positive smoking history and hypertension controlled by triple 
therapy. She took famotidine 50 mg three times daily for 12 days 
starting 10 days after first experiencing symptoms of COVID-
19. She noticed improvement in muscle aches and chest tightness 
in addition to those recorded in figure 2.
Patient 5 is a white man in his 50s iswith hypertension and 
hyperlipidaemia, both treated with medications, and posi-
tive smoking history. He took famotidine 80 mg three times 
daily for 8 days starting 6 days after first experiencing symp-
toms of COVID-19. He described ongoing increase of fatigue 
for another 7 days after starting famotidine; the only patient 
to describe worsening of any symptoms during this treatment 
period. However, he noticed improvement in respiratory symp-
toms within 2 days of starting famotidine.
Patient 6 is a Hispanic woman in her 20s with no pre- existing 
conditions. She took famotidine 80 mg three times daily starting 
9 days after first experiencing symptoms of COVID-19. She felt 
markedly better within 2 days of treatment but had mild dizzi-
ness and accelerated heart beats intermittently while taking 
famotidine.
Patient 7 is a black and Hispanic woman in her 20s with a 
BMI of 41 with no pre- existing conditions. She took famoti-
dine 80 mg three times daily for 12 days starting 6 days after 
first experiencing symptoms of COVID-19. Within 1 week of 
treatment, she reported relief of most symptoms. She reported 
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Figure 2 Patient level symptom scores. The longitudinal data for all reported symptoms are shown for individual patients. The mean is indicated as 
a dashed black line. The baseline scores are indicated adjacent to the y- axis. All patients reported baseline symptoms at 1. Colour- coded lines and dots 
for respective symptoms are ordered alphabetically and are slightly offset to avoid overlap. Day 0 indicates the day at which patients took the first 
dose of famotidine. Severity score: 1=not affected, 2=little affected, 3=affected, 4=severely affected. B, baseline; Pt, patient.
grade 1 dizziness, insomnia and dry skin concurrent with taking 
famotidine.
Patient 8 is a white man in his 70s with history of myocar-
dial infarction, surgery for a benign pancreatic tumour, chronic 
pancreatitis and chronic back pain. His diagnosis is based on 
clinical symptoms and signs and being from a high prevalence 
location, with all family members being clinically affected by 
COVID-19. He took Famotidine 60 mg two times daily for 5 days 
starting 26 days after first experiencing symptoms of COVID-
19. He reported a rapid improvement and being asymptomatic 
within 3 days of treatment. He routinely monitors his activity 
using an Oura Ring device and was able to provide readings 
on walking equivalence, calorie usage and activity score for the 
weeks before and after starting famotidine, which all showed 
marked improvements (figure 4B–D).
Patient 9 is a South Asian ex- smoker man in his 50s with 
history of hyperlipidaemia controlled by rosuvastatin. He took 
famotidine 60 mg two times daily for 21 days starting 2 days 
after first experiencing symptoms of COVID-19. He described 
improvement in his symptoms within 2 days of starting famoti-
dine. He reported possible famotidine associated mild forget-
fulness and gastroenterological symptoms that started while 
he was on famotidine but resolved before he stopped the 
medication.
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Figure 3 Normalised symptom scores of all patients. The mean 
longitudinal normalised symptom score for all patients is shown. The 
SE of the mean is indicated. Statistical comparisons by two- sided t- test 
in comparison with day 0, the day of starting famotidine. *P<0.05; 
***p<0.001; ****p<0.0001. NS, not significant.
Figure 4 Patient- level pulse oximetry and activity results. (A) The pulse oximetry data from two patients are displayed. (B–D) The device software 
provided display of weekly data relating to three metrices recorded using an Oura Ring are displayed for patient 8. The mean for each metric over the 
displayed period is indicated by a dashed line. Day 0 and week 0 represent the day and week of starting famotidine, respectively. Pt, patient.
Patient 10 is a white former smoker man in his 60s with a 
BMI of 37.5 without known pre- existing conditions. He took 
famotidine 20 mg three times daily for 5 days starting 7 days 
after first experiencing symptoms of COVID-19. He reported 
a universal improvement in symptoms within the first week of 
taking famotidine.
DISCuSSIOn
This case series provides patient- reported outcome measures 
for 10 consecutively enrolled non- hospitalised patients with 
COVID-19. They all noticed improvements in their condition 
in correlation with famotidine use at doses ranging from 60 mg 
to 240 mg daily. Based on published pharmacokinetic data for 
famotidine,8 9 we estimate that these treatment regimens would 
have resulted in peak plasma concentrations of approximately 
0.5–2 µM and average plasma concentrations of approximately 
0.15–0.7 µM famotidine, assuming normal kidney function. 
In concordance with the clinical evidence and consensus that 
famotidine is safe across a wide range of doses and frequencies, 
famotidine was very well tolerated by all patients. Given that 
famotidine has only minimal inhibitory effect on the hepatic 
cytochrome p450 system and low risk of clinically significant 
alterations in oxidative drug metabolism,10 11 it may be a safe 
drug for testing in a trial or clinical setting where patients self- 
administer the medication.
A pertinent aspect of this work is the exploration and appli-
cation of graded symptom scores and patient- reported outcome 
measures in tracking COVID-19 in the non- hospitalised setting 
using a four- point ordinal scale. Using these symptom scores, 
we were able to determine that all patients noticed a rapid 
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improvement in their condition within 24–48 hours of starting 
famotidine. Our quantitative approach to follow symptom 
severity may be a useful tool, in particular for outpatient studies, 
but requires validation. In addition, for all patients who were 
able to provide data, temperature readings, oxygen saturations 
and activity improved in correlation with taking famotidine. 
These findings suggest that famotidine may affect the course 
of COVID-19 but must be considered in the context of several 
limitations. Placebo effect, enrolment bias and recall bias12 for 
symptoms may affect our findings as is the case for the outcome 
measures of any non- blinded, non- controlled study, despite us 
attempting to minimise bias by asking non- leading questions. An 
improvement of symptoms was noticed within 48 hours by all 
individuals in this study, despite the symptomatic period prior to 
taking famotidine varying widely. There remains the possibility, 
however, that these changes may reflect treatment independent 
convalescence, as the natural course of COVID-19 in patients 
who do not require hospital admission is not well characterised.
Our case series suggests, but does not establish, a benefit from 
famotidine treatment in outpatients with COVID-19. Future 
work will investigate potential mechanisms of action and clinical 
relevance of famotidine. Mechanistically, famotidine could have 
a viral target, for example, one of the viral proteases, or a host 
target, resulting, for example, in modulation of the immunolog-
ical response to the virus. Clinically, we unreservedly share the 
opinion that well designed and informative studies of efficacy 
are required to evaluate candidate medications for COVID-19 
as for other diseases.13 A randomised phase III trial testing the 
efficacy of high dose intravenous famotidine three times daily 
in addition to hydroxychloroquine in hospitalised patients with 
COVID-19 has recently commenced (NCT04370262). An 
outpatient study of oral famotidine that investigates efficacy for 
symptom control, viral burden and disease outcome and assesses 
effects of medication use on long term immunity should be 
considered to establish if famotidine may be of use in controlling 
COVID-19 in individual patients while also reducing the risk of 
SARS- CoV-2 transmission.
COnCluSIOnS
The results presented in this case series suggest that high- dose 
oral famotidine is well tolerated and associated with improved 
self- reported outcomes in non- hospitalised patients with 
COVID-19.
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